(AOF) – The Bastide group announces an acceleration in its organic growth of 6.1% in the second quarter of 2023-2024, to 137.1 million euros and the confirmation of adjusted 2023-2024 objectives. The home health specialist is therefore targeting an annual turnover of around 530 million euros, adjusted for the impact linked to the sale of Distrimed, and is maintaining its current operating margin objective at least equal to that achieved on the 2022-2023 financial year, or 8.4%. Debt reduction is the group’s priority for the 2023-2024 financial year: it continues to study possible asset sales.
In home care, turnover came to 106.2 million euros, down 1.6% based on published data and 0.6% on a like-for-like basis. The “Respiratory” activity confirms its very good momentum and records a turnover of 89.5 million euros, up 12.4% (+11.7% organically) and now represents 56% of respiratory services. home health.
The “Nutrition-Infusion-Stomatherapy” activity posted a turnover of 69.4 million euros, up 11.8 and 8.7% organically driven by the good performance of the Diabetes and Nutrition activities. Infusion.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
